Literature DB >> 10769639

Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.

N Tørring1, P E Jørgensen, B S Sørensen, E Nexø.   

Abstract

BACKGROUND: The proliferation of androgen-independent prostate cancer cell lines has previously been shown to be influenced by an autocrine loop of the epidermal growth factor (EGF) system. This observation has alerted us to study the expression of ligands and receptors from the EGF-system in prostate cell lines.
METHODS: The expression of the EGF system was determined by quantitative RT-PCR and ELISA in the normal prostate epithelial cell line (PNT1A), in the androgen sensitive-(LNCaP), and the androgen-independent (DU145 and PC3) prostate cancer cell lines.
RESULTS: The expression of mRNA for the ligands TGF alpha, amphiregulin, HB-EGF and epiregulin were increased 10 to 100 fold in androgen-independent cells, as compared to LNCaP and PNT1A cells. Expression of mRNA for the ligands EGF and betacellulin and of the receptors HER1 and HER2 were similar in all lines investigated, except LNCaP cells which exhibit low expression of HER1. Similar results were obtained by ELISA.
CONCLUSIONS: The data indicates a selective up-regulation of a subclass of ligands of the EGF-system in androgen-independent prostate cancer cell lines. We suggest this could be a mechanism to escape androgen dependence in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769639

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

Authors:  Mengjia He; Qianni Jin; Cong Chen; Yifeng Liu; Xiangsen Ye; Yulin Jiang; Feihu Ji; Husun Qian; Delu Gan; Shujun Yue; Wei Zhu; Tingmei Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

Review 2.  Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders-an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop.

Authors:  Ricky McCullough; Jeremiah McCullough
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-17

3.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

4.  Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer.

Authors:  Lutz Trojan; Daniel Thomas; Thomas Knoll; Rainer Grobholz; Peter Alken; Maurice Stephan Michel
Journal:  Urol Res       Date:  2004-05

5.  Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.

Authors:  Mariano Hurtado; Juan José Lozano; Elisabeth Castellanos; Luis A López-Fernández; Keith Harshman; Carlos Martínez-A; Angel R Ortiz; Timothy M Thomson; Rosanna Paciucci
Journal:  Gut       Date:  2007-04-23       Impact factor: 23.059

6.  Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage.

Authors:  Daekee Lee; R Scott Pearsall; Sanjoy Das; Sudhansu K Dey; Virginia L Godfrey; David W Threadgill
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

7.  CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.

Authors:  Sreenivasa R Chinni; Hamilto Yamamoto; Zhong Dong; Aaron Sabbota; R Daniel Bonfil; Michael L Cher
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

8.  The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced.

Authors:  Boe Sandahl Sørensen; Niels Tørring; Mustafa Vakur Bor; Ebba Nexø
Journal:  Mol Cell Biochem       Date:  2004-05       Impact factor: 3.396

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

10.  Differential effects of EGFR ligands on endocytic sorting of the receptor.

Authors:  Kirstine Roepstorff; Michael Vibo Grandal; Lasse Henriksen; Stine Louise Jeppe Knudsen; Mads Lerdrup; Lene Grøvdal; Berthe Marie Willumsen; Bo van Deurs
Journal:  Traffic       Date:  2009-05-19       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.